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the context of a prospective trial, we cannot exclude the possibility
of multiple vaccine interactions; however, it appears unlikely at this
time.
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A Simple, Inexpensive, Rapid,
and Accurate Preclinical
Model for In-Stent Restenosis
With great interest we read the recent review by Schwartz et al. (1)
regarding preclinical animal restenosis models. Detailed descrip-
tions of the current available animal restenosis models, the patho-
physiology of in-stent restenosis (ISR), and the usefulness of
animal restenosis models to predict clinical outcomes are pre-
sented. In the final remarks it is concluded that preclinical models
are important but imperfect standards. A simple, inexpensive,
rapid, and accurate preclinical model would be useful. However, in
their description of available restenosis models, Schwartz et al. (1)
overlooked two important and recently developed animal models
of ISR. In these models, stents are implanted in the carotid artery
(2) or in the abdominal aorta (3) of the rat. Pathophysiological
processes of neoinitmal formation, such as thrombus formation,
inflammation, and smooth muscle cell proliferation, evolve in an
identical manner as seen in the rabbit iliac and pig coronary artery
models. Moreover, in the rat abdominal aorta model, a positive
correlation is found between the mean injury score and the
neointimal area (2,3).
Rat ISR models enable thorough pathophysiological studies, as
many antibodies to cellular proteins are available in the rat as
compared to rabbits and pigs. By elucidation of the pathophysiol-
ogy of ISR, more purposeful experiments to prevent ISR can be
carried out. Rat models of ISR could provide important indications
for the development of new anti-restenotic strategies (3). Gener-
ally, rat studies are preferable over rabbit or pig studies; only
mainstream surgical equipment is required, animal facilities have
large housing capacity for rats, and the costs for purchase are low.
Discrepancies between efficacy of anti-restenotic agents in
preclinical and clinical studies have caused skepticism about the rat
carotid artery model. For rat stent models this skepticism should be
tempered, because differences in pathophysiological mechanisms
between neointimal formation after balloon dilation alone and
stent implantation are evident. Furthermore, rapamycin-eluting
stents have been shown to inhibit neointimal formation in the rat
abdominal aorta, a clear relation between preclinical and clinical
outcomes in this model (3). In addition, these rat models enable
stent research in transgenic diabetic and hypertensive strains. This
offers a truer reflection of clinical settings in preclinical experi-
ments, and might result in a better prediction of efficacy of
anti-restenotic agents in clinical trials (2,3).
In conclusion, rat models are simple, inexpensive, rapid, and
accurate preclinical models for ISR.
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REPLY
We read with interest the comments of Dr. Langeveld and
colleagues concerning our recent review of preclinical restenosis
models (1). These investigators write that stenting the rat carotid
or abdominal artery provides a “simple, inexpensive, rapid, and
accurate preclinical model for in-stent restenosis.” We have several
comments in response regarding the utility of the rat model.
A useful in-stent restenosis animal model should accurately
predict: 1) safety, 2) efficacy, and 3) pathophysiologic mechanisms.
These are addressed as follows.
Safety. The major safety issues for stents are thrombosis (acute
or subacute) and neointimal thickening causing luminal stenosis.
Although the rat model sometimes induces stent thrombosis, it
does so to a lesser extent than the porcine and rabbit models. Total
occlusion and severe stent stenosis do not generally occur in the rat
model.
Efficacy. Rat carotid restenosis models were abandoned years ago
because virtually all therapies that were tested and effective in rats
later proved ineffective in patients. Such studies included
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